vs
Side-by-side financial comparison of Magnera Corp (MAGN) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Magnera Corp is the larger business by last-quarter revenue ($792.0M vs $622.0M, roughly 1.3× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs -4.3%, a 38.7% gap on every dollar of revenue. On growth, Magnera Corp posted the faster year-over-year revenue change (12.8% vs 4.8%). Over the past eight quarters, Magnera Corp's revenue compounded faster (54.9% CAGR vs 4.6%).
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
MAGN vs RPRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $792.0M | $622.0M |
| Net Profit | $-34.0M | $214.2M |
| Gross Margin | 12.2% | — |
| Operating Margin | 1.8% | 62.4% |
| Net Margin | -4.3% | 34.4% |
| Revenue YoY | 12.8% | 4.8% |
| Net Profit YoY | 43.3% | 2.9% |
| EPS (diluted) | $-0.95 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $792.0M | $622.0M | ||
| Q3 25 | — | $609.3M | ||
| Q2 25 | $839.0M | $578.7M | ||
| Q1 25 | $824.0M | $568.2M | ||
| Q4 24 | $702.0M | $593.6M | ||
| Q3 24 | $332.1M | $564.7M | ||
| Q2 24 | $556.0M | $537.3M | ||
| Q1 24 | $558.0M | $568.0M |
| Q4 25 | $-34.0M | $214.2M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | $-18.0M | $30.2M | ||
| Q1 25 | $-41.0M | $238.3M | ||
| Q4 24 | $-60.0M | $208.2M | ||
| Q3 24 | $-15.2M | $544.0M | ||
| Q2 24 | $19.0M | $102.0M | ||
| Q1 24 | $14.0M | $4.8M |
| Q4 25 | 12.2% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 10.7% | — | ||
| Q1 25 | 10.7% | — | ||
| Q4 24 | 10.1% | — | ||
| Q3 24 | 10.7% | — | ||
| Q2 24 | 6.6% | — | ||
| Q1 24 | 6.2% | — |
| Q4 25 | 1.8% | 62.4% | ||
| Q3 25 | — | 70.1% | ||
| Q2 25 | 1.5% | 36.3% | ||
| Q1 25 | 0.5% | 94.0% | ||
| Q4 24 | -3.1% | 60.9% | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 3.1% | 50.2% | ||
| Q1 24 | 3.8% | -13.0% |
| Q4 25 | -4.3% | 34.4% | ||
| Q3 25 | — | 47.3% | ||
| Q2 25 | -2.1% | 5.2% | ||
| Q1 25 | -5.0% | 41.9% | ||
| Q4 24 | -8.5% | 35.1% | ||
| Q3 24 | -4.6% | 96.3% | ||
| Q2 24 | 3.4% | 19.0% | ||
| Q1 24 | 2.5% | 0.8% |
| Q4 25 | $-0.95 | $0.49 | ||
| Q3 25 | — | $0.67 | ||
| Q2 25 | $-0.51 | $0.07 | ||
| Q1 25 | $-1.15 | $0.55 | ||
| Q4 24 | $-1.69 | $0.46 | ||
| Q3 24 | $-0.33 | $1.21 | ||
| Q2 24 | $0.60 | $0.23 | ||
| Q1 24 | $0.44 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $264.0M | $618.7M |
| Total DebtLower is stronger | $1.9B | $9.0B |
| Stockholders' EquityBook value | $1.0B | $9.7B |
| Total Assets | $3.9B | $19.6B |
| Debt / EquityLower = less leverage | 1.86× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $264.0M | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | $276.0M | $631.9M | ||
| Q1 25 | $282.0M | $1.1B | ||
| Q4 24 | $215.0M | $929.0M | ||
| Q3 24 | $230.0M | $950.1M | ||
| Q2 24 | $33.9M | $1.8B | ||
| Q1 24 | $30.2M | $843.0M |
| Q4 25 | $1.9B | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | $2.0B | $8.0B | ||
| Q1 25 | $2.0B | $7.6B | ||
| Q4 24 | $2.0B | $7.6B | ||
| Q3 24 | $2.0B | $7.6B | ||
| Q2 24 | $877.4M | $7.6B | ||
| Q1 24 | $884.7M | $6.1B |
| Q4 25 | $1.0B | $9.7B | ||
| Q3 25 | — | $9.6B | ||
| Q2 25 | $1.1B | $9.5B | ||
| Q1 25 | $1.1B | $9.8B | ||
| Q4 24 | $1.1B | $10.3B | ||
| Q3 24 | $2.1B | $10.3B | ||
| Q2 24 | $2.4B | $9.8B | ||
| Q1 24 | $2.4B | $9.9B |
| Q4 25 | $3.9B | $19.6B | ||
| Q3 25 | — | $19.3B | ||
| Q2 25 | $4.1B | $18.3B | ||
| Q1 25 | $4.1B | $17.6B | ||
| Q4 24 | $4.0B | $18.2B | ||
| Q3 24 | $2.8B | $18.0B | ||
| Q2 24 | $1.5B | $17.7B | ||
| Q1 24 | $1.5B | $16.1B |
| Q4 25 | 1.86× | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | 1.77× | 0.84× | ||
| Q1 25 | 1.83× | 0.78× | ||
| Q4 24 | 1.80× | 0.74× | ||
| Q3 24 | 0.91× | 0.74× | ||
| Q2 24 | 0.37× | 0.78× | ||
| Q1 24 | 0.36× | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $827.1M |
| Free Cash FlowOCF − Capex | $-13.0M | — |
| FCF MarginFCF / Revenue | -1.6% | — |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $827.1M | ||
| Q3 25 | — | $702.6M | ||
| Q2 25 | $0 | $364.0M | ||
| Q1 25 | $65.0M | $596.1M | ||
| Q4 24 | $-58.0M | $742.5M | ||
| Q3 24 | $12.2M | $703.6M | ||
| Q2 24 | $38.0M | $658.2M | ||
| Q1 24 | $20.0M | $664.6M |
| Q4 25 | $-13.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $42.0M | — | ||
| Q4 24 | $-74.0M | — | ||
| Q3 24 | $3.6M | — | ||
| Q2 24 | $23.0M | — | ||
| Q1 24 | $12.5M | — |
| Q4 25 | -1.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | -10.5% | — | ||
| Q3 24 | 1.1% | — | ||
| Q2 24 | 4.1% | — | ||
| Q1 24 | 2.2% | — |
| Q4 25 | 1.9% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 2.8% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 2.6% | — | ||
| Q2 24 | 2.7% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | 2.00× | 6.45× | ||
| Q1 24 | 1.43× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MAGN
| Other | $451.0M | 57% |
| United States And Canada | $341.0M | 43% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
